Zhenyu Ji

Tianjin Medical University Cancer Institute and Hospital — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.6kcitations101works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(38), Cancer-related gene regulation(16), HER2/EGFR in Cancer Research(12), Computational Drug Discovery Methods(11), Synthesis and biological activity(11)

Publications101 total

An artificial intelligence system for qualified mucosal observation time during colonoscopic withdrawal
npj Digital Medicine·2025Open Access
[A retrospective study of BRAF inhibitors and EGFR inhibitors combined with immune checkpoint inhibitors in patients with microsatellite stable, BRAF V600E mutated metastatic colorectal cancer].
PubMed·2025
Deep Learning for Automatic T-Staging Prediction of Laryngeal Cancer Using CT Scan and Radiology Report
International Journal of Radiation Oncology*Biology*Physics·2025
Mo1220: DEVELOPMENT AND VALIDATION OF A PREDICTION MODEL FOR ADVANCED COLORECTAL NEOPLASIA IN THE CHINESE ASYMPTOMATIC POPULATIONS
Gastroenterology·2025
Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against Kit-mutant melanoma
Bioactive Materials·2024· 3 citedOpen Access
Analysis of Variants Induced by Combined Ex Vivo Irradiation and In Vivo Tumorigenesis Suggests a Role for the ZNF831 p.R1393Q Variant in Cutaneous Melanoma Development
Journal of Investigative Dermatology·2024· 1 cited
173 Geospatial and temporal clustering of melanoma incidence and mortality rates identifies distinct trend groups
Journal of Investigative Dermatology·2024Open Access
Geotemporal Analysis of Melanoma Incidence and Mortality Identifies Distinct Clusters of Trends within the United States Between 2001 and 2019
Journal of Investigative Dermatology·2024· 1 citedOpen Access
Molecular Analysis of Murine KitK641E Melanoma Progression
JID Innovations·2024· 1 citedOpen Access
[The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study].
PubMed·2023· 1 cited
Supplementary Figure S1 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
2023Open Access
Supplementary Figure S3 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
2023Open Access
Data from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
2023Open Access
Supplementary Figure S5 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
2023Open Access
Supplementary Figure S4 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
2023Open Access
Supplementary Figure S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
2023Open Access
Supplementary Figure S1 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
2023Open Access
Supplementary Figure S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
2023Open Access
Data from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
2023Open Access
Supplementary Figure S3 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Hensin Tsao(26), Keith T. Flaherty(14), Raj Kumar(12), Ching-Ni Jenny Njauw(12), Anpuchchelvi Rajadurai(10), Michael Taylor(8), Benchun Miao(7), Dennie T. Frederick(5), Jennifer A. Wargo(4), Nathanael S. Gray(4), Michael D. Taylor(4), Fang Mei(3), Li Tan(3), Hwan Geun Choi(3), Alexander Marzuka-Alcalá(3), Göran Jönsson(3), Qiuyue Nie(3), Gong‐Li Tang(3), Liping Dai(3), Cong Ding(3)